Doxazosin detailed information
 | |
| Clinical data | |
|---|---|
| Routes of administration | oral |
| ATC code | |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Bioavailability | 65% |
| Protein binding | 98% |
| Metabolism | Hepatic |
| Elimination half-life | 22 hours |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| E number | {{#property:P628}} |
| ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
| Chemical and physical data | |
| Formula | C23H25N5O5 |
| Molar mass | 451.475 g/mol |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
For patient information, click here
Doxazosin mesylate, a quinazoline compound sold by Pfizer under the brand name Cardura®, is an alpha blocker used to treat high blood pressure and benign prostatic hyperplasia.
It is an alpha adrenergic receptor blocker which inhibits the binding of norepinephrine to alpha receptors in the autonomic nervous system. The primary effect of this blockage is relaxed vascular smooth muscle tone (vasodilation), which decreases peripheral vascular resistance, leading to decreased blood pressure.
Efficacy
In March 2000, the ALLHAT study stopped the arm of its trial looking at alpha blockers because doxazosin (Cardura) was less effective than a simple diuretic. Patients on Cardura had a 25% higher rate of cardiovascular disease and twice the rate of congestive heart failure as patients on diuretics[1]. Pfizer, aware of the results before publication, launched a sophisticated damage control campaign in early 2000, and sales were largely unaffected despite the dangers highlighted by the study[2].
External links
- Information about Cardura from rxlist.com
- BMJ article about Cardura.
- Article about Cardura
- Pfizer Site
References
- ↑ Piller LB, Davis BR, Cutler JA; et al. (2002). "Validation of Heart Failure Events in the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Participants Assigned to Doxazosin and Chlorthalidone". Curr Control Trials Cardiovasc Med. 3 (1): 10. doi:10.1186/1468-6708-3-10. PMID 12459039. Unknown parameter
|month=ignored (help) - ↑ "Marketing: Spin doctors soft pedal data on antihypertensives". BMJ. 2003-01-18. Retrieved 2008-05-26.
- Pages with script errors
- Pages with citations using unsupported parameters
- CS1 maint: Explicit use of et al.
- CS1 maint: Multiple names: authors list
- Drugs with non-standard legal status
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Chemical articles with unknown parameter in Infobox drug
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Articles containing unverified chemical infoboxes
- Alpha blockers
- Drugs